@entity2915 based on dose-intensified @entity1891 , @entity619 , and asparaginase in adult XXXX salvage therapy.

@entity1 @entity632 @entity981 @entity455 @entity786 @entity4445 @entity619 @entity2915 @entity1891
The prognosis of adult @entity1 with relapsed @entity981 ( @entity981 ) remains poor. Recent studies in adolescents and young adults reported better outcomes when therapy was intensified. Based on hyper-CVAD ( @entity786 / @entity1891 / @entity632 / @entity619 ) as a backbone, we designed an augmented version with intensified doses of @entity1891 , @entity619 , and asparaginase ( @entity4445 in the first 62 @entity1 and pegaspargase in the remainder) starting from course 1. Ninety @entity1 have been enrolled, with a median age of 34 years (range, 14-70 years). Most @entity1 (78%) had pre-B @entity981 and were in first salvage (76%), with a first remission duration of 12.6 months (range, 1-78 months). Ten @entity1 had primary refractory disease. Of 88 evaluable @entity1 , 41 (47%) achieved complete remission (CR), with a median time to CR of 29 days (range, 18-80 days). Eight @entity1 (9%) died within the first 30 days. Median CR duration, progression-free survival, and overall survival were 5, 6.2, and 6 months, respectively. Median overall survival of CR @entity1 was 10.2 months (range, 1.4-69.5+ months). Twenty-eight @entity1 (32%) proceeded to stem cell transplantation. @entity455 were frequent. Pegaspargase was equally effective and easier to administer than @entity4445 . @entity2915 may be suitable to be studied in younger adults with untreated @entity981 .
